Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: A cross-sectional study
Open Access
- 15 May 2011
- journal article
- Published by Springer Science and Business Media LLC in Nutrition Journal
- Vol. 10 (1), 49
- https://doi.org/10.1186/1475-2891-10-49
Abstract
Background Previous studies suggested that the abnormality of metabolism is a newly identified risk factor in HBV-related hepatocellular carcinoma (HCC). The association between metabolic factors and hepatocellular carcinoma (HCC) has not been clarified up to now. This study was conducted to investigate the prevalence of metabolic abnormalities in HCC and to probe the association between metabolic parameters and liver function as well, so as to evaluate the interactions between metabolism and the development of HBV-related HCC. Methods Totally 179 cases of HBV-related HCC, who were surgically treated and pathologically confirmed were enrolled. HBV carriers (n = 100) and healthy controls (n = 150) were recruited from routine physical examination during the same period. Body mass index (BMI) was obtained from medical documentation. All the metabolic-related parameters and liver function tests were determined with routine biochemical or immunological analytic methods. Malondialdehyde (MDA) and total antioxidant capacity(TAOC)were detected by chemical analytic methods. A stratified analysis was conducted according to BMI, glycated albumin (GA), free fatty acids (FFA), and the relationships between the metabolic-related parameters and liver functions were analyzed in HCC and control subjects. Results HCC group showed significantly high levels of mean BMI, serum glucose, low serum lipids levels than controls (P < 0.05). Acquired by stratified analysis, the higher the BMI, the higher level of insulin and homeostasis model assessment for insulin resistance (HOMA-IR) (P < 0.01) were found in HCC patients. Elevated level of MDA and γ-glutamyltransferase (GGT) were revealed in those with high serum FFA level for the first time. Strong associations between metabolic factors and liver function were shown in HCC (P < 0.05). Higher GA level was strongly associated with increased risk of cancer compared to healthy controls (OR = 9.87, 95% confidence interval: 1.86~52.29). Serum triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels were negative contributory factors for HCC (OR = 0.05, 95% confidence interval: 0.01~0.27 and OR = 0.32, 95% confidence interval, 0.11~0.95: respectively). Conclusions Metabolic abnormalities are closely associated with the occurrence and development of HBV-related HCC. Oxidative stress and/or lipid peroxidation might be involved in the pathogenesis and acceleration of liver function impairments in HCC.Keywords
This publication has 51 references indexed in Scilit:
- Newly diagnosed diabetes mellitus as a risk factor for serious liver diseaseCMAJ : Canadian Medical Association Journal, 2010
- Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II)Cancer Causes & Control, 2008
- Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysisHepatology, 2008
- Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver diseaseJournal of Zhejiang University-SCIENCE B, 2008
- Metabolic SyndromeCirculation, 2007
- Overweight and obesity in ChinaBMJ, 2006
- A population-based study investigating the association between metabolic syndrome and Hepatitis B/C infection (Keelung Community-based Integrated Screening Study No. 10)International Journal of Obesity, 2006
- NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United StatesHepatology, 2002
- NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United StatesHepatology, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001